GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Perceptions or reality: Which skills are employers missing?
Malta Maritime Forum CEO Kevin J Borg, while participating at a national conference, emphasised the importance of employer organisations catering ...
TradeMalta CEO appointed Vice President of the Board at Trade Promotion Europe
Trade Promotion Europe is a non-profit association of national and regional trade and agri-food promotion organisations.
‘As leaders we need to understand how to change our relationship with change and uncertainty’
Pierre Mallia lists five 'laws' which help him stay calm and focused even when he feels a storm looming on ...
5 tips to party like a ‘proper’ boss this festive season
Should the boss attend the office party? The simple answer is yes, however there are ways and means to go ...
